FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C. Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J. Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J. O’Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet

Journal ArticleOPEN ACCESS

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Conroy T
Hammel P
Hebbar M
et al.

New England Journal of Medicine (2018) 379(25) 2395-2406

DOI: 10.1056/nejmoa1809775

2.5kCitations

1.5kReaders

Abstract

Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine ...

Cite

CITATION STYLE

APA

Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., … Bachet, J.-B. (2018). FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine, 379(25), 2395–2406. https://doi.org/10.1056/nejmoa1809775

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Abstract

Cite

Register to see more suggestions